Aurora Cannabis Inc. announced its financial results for the fiscal year ending March 31, 2025, highlighting a record annual global medical cannabis net revenue of $244.4 million. This figure represents a 39% increase compared to the previous year. The company also reported an adjusted EBITDA of $49.7 million, which shows a substantial 261% growth year-over-year, alongside a positive free cash flow of $9.9 million.
In the fourth quarter of 2025, Aurora’s international revenue more than doubled, contributing to 61% of its total global medical cannabis net revenue. Additionally, revenue from plant propagation grew by 32%. Despite a reported decline in consumer cannabis revenue, the company has maintained strong profit margins and showcased a solid financial position with $185.3 million in cash and no debt.
Aurora Cannabis identified and corrected minor financial reporting errors from prior periods, which were assessed as immaterial and did not necessitate amendments to past financial statements.
Analysts have assigned a Hold rating to Aurora Cannabis stock (TSE: ACB), with a price target set at C$11.00. The current market cap stands at C$457.2 million, and the average trading volume is 447,684 shares.
TipRanks’ AI Analyst rated Aurora Cannabis as Neutral, scoring it a 50. This reflects both ongoing financial challenges and encouraging operational advancements. The positive earnings call and strategic corporate decisions indicate growth potential, but persistent financial hurdles and high valuation pressures the overall score.
Aurora Cannabis is recognized as a leading global medical cannabis company based in Canada, focusing on producing and distributing medical cannabis products across various markets, including Australia, Germany, Poland, and the UK. The company’s commitment to improving profitability and operational performance remains essential as it navigates the evolving cannabis landscape.
Czech 
English 
Spanish 
German